Research analysts at Singular Research started coverage on shares of Abbott Laboratories (NYSE:ABT) in a report released on Monday, ARN reports. The firm set a “sell” rating and a $30.00 price target on the stock. Singular Research’s price objective suggests a potential downside of 24.45% from the company’s current price. Abbott Laboratories (NYSE:ABT) shares after opening at $39.19 on last trade day and at the end of the day closed at $38.97. Company price to sales ratio in past twelve months was calculated as 2.77 and price to cash ratio as 7.46. Abbott Laboratories (NYSE:ABT)showed a negative weekly performance of -1.52%.
Senior Analyst Glenn Novarro of RBC Capital Markets foresees Johnson & Johnson (NYSE:JNJ) experiencing strong pharmaceutical growth and a recovery of consumer sales growth in 2014, followed by outperformance in operating margins in 2015. Johnson & Johnson (NYSE:JNJ) shares fell -0.20% in last trading session and ended the day on $92.81. JNJ return on equity ratio is recorded as 19.70% and its return on assets is 10.90%. Johnson & Johnson (NYSE:JNJ) yearly performance is 20.80%.
A banker considers Mylan Inc (NASDAQ:MYL) a good target for Perrigo and believes the company is reconsidering big deals, says dealReporter. Mylan Inc (NASDAQ:MYL) shares moved up 1.17% in last trading session and was closed at $52.63, while trading in range of $51.86 – $53.46. Mylan Inc (NASDAQ:MYL) year to date (YTD) performance is 21.27%.
Arena Pharmaceuticals (NASDAQ:ARNA) was the recipient of a large decline in short interest in January. As of February 14th, there was short interest totalling 59,248,778 shares, a decline of 8.9% from the January 31st total of 65,038,639 shares, Analyst Ratings Network reports. Approximately 27.3% of the shares of the company are short sold. Based on an average daily volume of 5,843,561 shares, the days-to-cover ratio is currently 10.1 days. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) weekly performance is -8.85%. On last trading day company shares ended up $6.49. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)distance from 50-day simple moving average (SMA50) is -3.18%. Analysts mean target price for the company is $8.71.